Discontinuation Rate of Newly Prescribed Donepezil in Alzheimer's Disease Patients in Asia
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background and Purpose The rate of donepezil discontinuation and the underlying reasons for discontinuation in Asian patients with Alzheimer’s disease (AD) are currently unknown. We aimed to determine the treatment discontinuation rates in AD patients who had newly been prescribed donepezil in routine clinical practice in Asia. Methods This 1-year observational study involved 38 institutions in seven Asian countries, and it evaluated 398 participants aged 50–90 years with a diagnosis of probable AD and on newly prescribed donepezil monotherapy. The primary endpoint was the rate of donepezil discontinuation over 1 year. Secondary endpoints included the reason for discontinuation, treatment duration, changes in cognitive function over the 1-year study period, and compliance as assessed using a clinician rating scale (CRS) and visual analog scale (VAS). Results Donepezil was discontinued in 83 (20.9%) patients, most commonly due to an adverse event (43.4%). The mean treatment duration was 103.67 days in patients who discontinued. Among patients whose cognitive function was assessed at baseline and 1 year, there were no significant changes in scores on the Mini-Mental State Examination, Montreal Cognitive Assessment, and Trail-Making Test–Black and White scores, whereas the Clinical Dementia Rating score increased significantly (p<0.001). Treatment compliance at 1 year was 96.8% (306/316) on the CRS and 92.6±14.1% (mean±standard deviation) on the VAS. Conclusions In patients on newly prescribed donepezil, the primary reason for discontinuation was an adverse event. Cognitive assessments revealed no significant worsening at 1 year, indicating that continuous donepezil treatment contributes to the maintenance of cognitive function.
Abstract
Background and Purpose The rate of donepezil discontinuation and the underlying reasons for discontinuation in Asian patients with Alzheimer’s disease (AD) are currently unknown. We aimed to determine the treatment discontinuation rates in AD patients who had newly been prescribed donepezil in routine clinical practice in Asia. Methods This 1-year observational study involved 38 institutions in seven Asian countries, and it evaluated 398 participants aged 50–90 years with a diagnosis of probable AD and on newly prescribed donepezil monotherapy. The primary endpoint was the rate of donepezil discontinuation over 1 year. Secondary endpoints included the reason for discontinuation, treatment duration, changes in cognitive function over the 1-year study period, and compliance as assessed using a clinician rating scale (CRS) and visual analog scale (VAS). Results Donepezil was discontinued in 83 (20.9%) patients, most commonly due to an adverse event (43.4%). The mean treatment duration was 103.67 days in patients who discontinued. Among patients whose cognitive function was assessed at baseline and 1 year, there were no significant changes in scores on the Mini-Mental State Examination, Montreal Cognitive Assessment, and Trail-Making Test–Black and White scores, whereas the Clinical Dementia Rating score increased significantly (p<0.001). Treatment compliance at 1 year was 96.8% (306/316) on the CRS and 92.6±14.1% (mean±standard deviation) on the VAS. Conclusions In patients on newly prescribed donepezil, the primary reason for discontinuation was an adverse event. Cognitive assessments revealed no significant worsening at 1 year, indicating that continuous donepezil treatment contributes to the maintenance of cognitive function.
참고문헌 (38)
- Kontis V, "Future life expectancy in 35 industrialised countries : projections with a Bayesian model ensemble", Lancet, 389, pp.1323~1335 (2017)
- "Dementia fact sheet"[URL]
- "10 facts on dementia"[URL]
- "Alzheimer’s Australia. Dementia in the Asia Pacific Region"[URL]
- Rogers SL, "Donepezil improves cognition and global function in Alzheimer disease : a 15-week, double-blind, placebo-controlled study", Arch Intern Med, 158, pp.1021~1031 (1998)
- Rogers SL, "A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease", Neurology, 50, pp.136~145 (1998)
- Burns A, "The effects of donepezil in Alzheimer’s disease-results from a multinational trial", Dement Geriatr Cogn Disord, 10, pp.237~244 (1999)
- Winblad B, "A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD", Neurology, 57, pp.489~495 (2001)
- Winblad B, "Donepezil in patients with severe Alzheimer’s disease : double-blind, parallel-group, placebo-controlled study", Lancet, 367, pp.1057~1065 (2006)
- Emilien G, "Prospects for pharmacological intervention in Alzheimer disease", Arch Neurol, 57, pp.454~459 (2000)
- Rogers SL, "Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease : an interim analysis of the results of a US multicentre open label extension study", Eur Neuropsychopharmacol, 8, pp.67~75 (1998)
- Cavedo E, "Reduced basal forebrain atrophy progression in a randomized donepezil trial in prodromal Alzheimer’s disease", Sci Rep, 7, pp.11706~ (2017)
- Dubois B, "Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer’s disease", Alzheimers Dement, 11, pp.1041~1049 (2015)
- Noh MY, "Neuroprotective effects of donepezil through inhibition of GSK-3 activity in amyloid-βinduced neuronal cell death", J Neurochem, 108, pp.1116~1125 (2009)
- Noh MY, "Neuroprotective effects of donepezil against Aβ42-induced neuronal toxicity are mediated through not only enhancing PP2A activity but also regulating GSK-3β and nAChRs activity", J Neurochem, 127, pp.562~574 (2013)
- Rogers SL, "The efficacy and safety of donepezil in patients with Alzheimer’s disease : results of a US multicentre, randomized, double-blind, placebo-controlled trial", Dement Geriatr Cogn Disord, 7, pp.293~303 (1996)
- Rogers SL, "Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease : final analysis of a US multicentre open-label study", Eur Neuropsychopharmacol, 10, pp.195~203 (2000)
- Birks JS, "Donepezil for dementia due to Alzheimer’s disease", Cochrane Database Syst Rev, (6), pp.CD001190~ (2018)
- Klatte ET, "Combination therapy of donepezil and vitamin E in Alzheimer disease", Alzheimer Dis Assoc Disord, 17, pp.113~116 (2003)
- Courtney C, "Long-term donepezil treatment in 565 patients with Alzheimer’s disease(AD2000) : randomised double-blind trial", Lancet, 363, pp.2105~2115 (2004)
- Blanco-Silvente L, "Discontinuation, efficacy, and safety of cholinesterase inhibitors for Alzheimer’s disease : a meta-analysis and metaregression of 43 randomized clinical trials enrolling 16 106 patients", Int J Neuropsychopharmacol, 20, pp.519~528 (2017)
- Doody RS, "Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease", Arch Neurol, 58, pp.427~433 (2001)
- Burns A, "Efficacy and safety of donepezil over 3 years : an open-label, multicentre study in patients with Alzheimer’s disease", Int J Geriatr Psychiatry, 22, pp.806~812 (2007)
- Maxwell CJ, "Persistence and adherence with dementia pharmacotherapy : relevance of patient, provider, and system factors", Can J Psychiatry, 59, pp.624~631 (2014)
- Taipale H, "Antidementia drug use among community-dwelling individuals with Alzheimer’s disease in Finland : a nationwide registerbased study", Int Clin Psychopharmacol, 29, pp.216~223 (2014)
- Ndukwe HC, "Donepezil adherence, persistence and time to first discontinuation in a three-year follow-up of older people", Dement Geriatr Cogn Dis Extra, 5, pp.482~491 (2015)
- Fisher A, "Cholinesterase inhibitor utilization : the impact of provincial drug policy on discontinuation", Value Health, 19, pp.688~696 (2016)
- Fisher A, "Tolerability of cholinesterase inhibitors : a population-based study of persistence, adherence, and switching", Drugs Aging, 34, pp.221~231 (2017)
- Umegaki H, "Discontinuation of donepezil for the treatment of Alzheimer’s disease in geriatric practice", Int Psychogeriatr, 20, pp.800~806 (2008)
- 안소현, "Drug persistency of cholinesterase inhibitors for patients with dementia of Alzheimer type in Korea", Archives of Pharmacal Research, 38(6), pp.1255~1262 (2015), 대한약학회
- McKhann G, "Clinical diagnosis of Alzheimer’s disease : report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease", Neurology, 34, pp.939~944 (1984)
- Amuah JE, "Persistence with cholinesterase inhibitor therapy in a populationbased cohort of patients with Alzheimer’s disease", Pharmacoepidemiol Drug Saf, 19, pp.670~679 (2010)
- Cummings JL, "High-dose donepezil(23 mg", day)for the treatment of moderate and severe Alzheimer’s disease : drug profile and clinical guidelines, 2013, pp.19, 294~301
- Doody RS, "Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer’s disease", Dement Geriatr Cogn Disord, 12, pp.295~300 (2001)
- Baek MJ, "The validity and reliability of the Mini-Mental State Examination-2 for detecting mild cognitive impairment and Alzheimer’s disease in a Korean population", PLoS One, 11, pp.e0163792~ (2016)
- Cheng J, "Donepezil’s effects on brain functions of patients with Alzheimer disease : a regional homogeneity study based on resting-state functional magnetic resonance imaging", Clin Neuropharmacol, 42, pp.42~48 (2019)
- Mohs RC, "A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients", Neurology, 57, pp.481~488 (2001)
- Gauthier S, "Effects of donepezil on activities of daily living : integrated analysis of patient data from studies in mild, moderate and severe Alzheimer’s disease", Int Psychogeriatr, 22, pp.973~983 (2010)